HRP20220019T1 - Pentaciklički spoj - Google Patents
Pentaciklički spoj Download PDFInfo
- Publication number
- HRP20220019T1 HRP20220019T1 HRP20220019TT HRP20220019T HRP20220019T1 HR P20220019 T1 HRP20220019 T1 HR P20220019T1 HR P20220019T T HRP20220019T T HR P20220019TT HR P20220019 T HRP20220019 T HR P20220019T HR P20220019 T1 HRP20220019 T1 HR P20220019T1
- Authority
- HR
- Croatia
- Prior art keywords
- thieno
- pharmaceutically acceptable
- acceptable salt
- pyrimido
- diazepine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 9
- 150000003839 salts Chemical class 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- FXPGUOIKUKRLJQ-ZYHUDNBSSA-N (17R,21R)-7,15-dimethyl-10-thia-1,7,12,15-tetrazapentacyclo[11.8.0.03,11.04,9.017,21]henicosa-3(11),4(9),12-triene-2,16-dione Chemical compound CN1CC=2N([C@H]3[C@H](C1=O)CCC3)C(C1=C(N=2)SC2=C1CCN(C2)C)=O FXPGUOIKUKRLJQ-ZYHUDNBSSA-N 0.000 claims 2
- FXPGUOIKUKRLJQ-CMPLNLGQSA-N (17S,21R)-7,15-dimethyl-10-thia-1,7,12,15-tetrazapentacyclo[11.8.0.03,11.04,9.017,21]henicosa-3(11),4(9),12-triene-2,16-dione Chemical compound CN1CC=2N([C@H]3[C@@H](C1=O)CCC3)C(C1=C(N=2)SC2=C1CCN(C2)C)=O FXPGUOIKUKRLJQ-CMPLNLGQSA-N 0.000 claims 2
- FXPGUOIKUKRLJQ-JQWIXIFHSA-N (17S,21S)-7,15-dimethyl-10-thia-1,7,12,15-tetrazapentacyclo[11.8.0.03,11.04,9.017,21]henicosa-3(11),4(9),12-triene-2,16-dione Chemical compound CN1CC=2N([C@@H]3[C@@H](C1=O)CCC3)C(C1=C(N=2)SC2=C1CCN(C2)C)=O FXPGUOIKUKRLJQ-JQWIXIFHSA-N 0.000 claims 2
- SSAATEWXIYOLQT-UHFFFAOYSA-N 19-fluoro-7,15-dimethyl-10-thia-1,7,12,15-tetrazapentacyclo[11.9.0.03,11.04,9.017,22]docosa-3(11),4(9),12,17(22),18,20-hexaene-2,16-dione Chemical compound FC=1C=CC2=C(C(N(CC=3N2C(C2=C(N=3)SC3=C2CCN(C3)C)=O)C)=O)C=1 SSAATEWXIYOLQT-UHFFFAOYSA-N 0.000 claims 2
- YKFDFHUUDLXYIJ-UHFFFAOYSA-N 7,15-dimethyl-10,18-dithia-1,7,12,15-tetrazapentacyclo[11.8.0.03,11.04,9.017,21]henicosa-3(11),4(9),12,17(21),19-pentaene-2,16-dione Chemical compound CN1CC=2N(C3=C(C1=O)SC=C3)C(C1=C(N=2)SC2=C1CCN(C2)C)=O YKFDFHUUDLXYIJ-UHFFFAOYSA-N 0.000 claims 2
- MBDLEUICTWNYLK-UHFFFAOYSA-N 7,15-dimethyl-10,20-dithia-1,7,12,15-tetrazapentacyclo[11.8.0.03,11.04,9.017,21]henicosa-3(11),4(9),12,17(21),18-pentaene-2,16-dione Chemical compound CN1CC=2N(C3=C(C1=O)C=CS3)C(C1=C(N=2)SC2=C1CCN(C2)C)=O MBDLEUICTWNYLK-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (14)
1. Spoj odabran iz skupine koju čine:
3-fluor-6,11-dimetil-6,7,10,11,12,13-heksahidrobenzo[f]pirido[4",3":4',5']tieno[2',3':4,5]pirimido[1,2-a][1,4]diazepin-5,14-dion:
[image]
5,10-dimetil-5,6,9,10,11,12-heksahidropirido[4",3":4',5']tieno[2',3':4,5]pirimido[1,2-a]tieno[2,3-f][1,4]diazepin-4,13-dion:
[image]
5,10-dimetil-5,6,9,10,11,12-heksahidropirido[4",3":4',5']tieno[2',3':4,5]pirimido[1,2-a]tieno[3,2-f][1,4]diazepin-4,13-dion:
[image]
(3aS,14aR)-5,10-dimetil-3,3a,5,6,9,10,11,12-oktahidro-1H-ciklopenta[f]pirido[4",3":4',5']tieno[2',3':4,5]pirimido[1,2-a][1,4]diazepin-4,13(2H,14aH)-dion:
[image]
(3aR,14aR)-5,10-dimetil-3,3a,5,6,9,10,11,12-oktahidro-1H-ciklopenta[f]pirido[4",3":4',5']tieno[2',3':4,5]pirimido[1,2-a][1,4]diazepin-4,13(2H,14aH)-dion:
[image]
i
(3aS,14aS)-5,10-dimetil-3,3a,5,6,9,10,11,12-oktahidro-1H-ciklopenta[f]pirido[4",3":4',5']tieno[2',3':4,5]pirimido[1,2-a][1,4]diazepin-4,13(2H,14aH)-dion:
[image]
ili njihova farmaceutski prihvatljiva sol.
2. 3-Fluor-6,11-dimetil-6,7,10,11,12,13-heksahidrobenzo[f]pirido[4",3":4',5']tieno[2',3':4,5]pirimido[1,2-a][1,4]diazepin-5,14-dion ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 1:
[image]
3. 5,10-Dimetil-5,6,9,10,11,12-heksahidropirido[4",3":4',5']tieno[2',3':4,5]pirimido[1,2-a]tieno[2,3-f][1,4]diazepin-4,13-dion ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 1:
[image]
4. 5,10-Dimetil-5,6,9,10,11,12-heksahidropirido[4",3":4',5']tieno[2',3':4,5]pirimido[1,2-a]tieno[3,2-f][1,4]diazepin-4,13-dion ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 1:
[image]
5. (3aS,14aR)-5,10-Dimetil-3,3a,5,6,9,10,11,12-oktahidro-1H-ciklopenta[f]pirido[4",3":4',5']tieno[2',3':4,5]pirimido[1,2-a][1,4]diazepin-4,13(2H,14aH)-dion ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 1:
[image]
6. (3aR,14aR)-5,10-Dimetil-3,3a,5,6,9,10,11,12-oktahidro-1H-ciklopenta[f]pirido[4",3":4',5']tieno[2',3':4,5]pirimido[1,2-a][1,4]diazepin-4,13(2H,14aH)-dion ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 1:
[image]
7. (3aS,14aS)-5,10-Dimetil-3,3a,5,6,9,10,11,12-oktahidro-1H-ciklopenta[f]pirido[4",3":4',5']tieno[2',3':4,5]pirimido[1,2-a][1,4]diazepin-4,13(2H,14aH)-dion ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 1:
[image]
8. Farmaceutski pripravak naznačen time što sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od patentnih zahtjeva 1 do 7 i jedan ili više farmaceutski prihvatljivih aditiva.
9. Terapeutsko sredstvo za upotrebu u liječenju Alzheimerove bolesti, naznačeno time što sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1 do 7.
10. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 7 za upotrebu u liječenju Alzheimerove bolesti.
11. Terapeutsko sredstvo za upotrebu u liječenju demencije s Lewyjevim tijelima naznačeno time što sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1 do 7.
12. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 to 7 za upotrebu u liječenju demencije s Lewyjevim tijelima.
13. Terapeutsko sredstvo za upotrebu u liječenju Parkinsonove bolesti s demencijom, naznačeno time što sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1 do 7.
14. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 7 za upotrebu u liječenju Parkinsonove bolesti s demencijom.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017172169 | 2017-09-07 | ||
PCT/JP2018/032797 WO2019049869A1 (ja) | 2017-09-07 | 2018-09-05 | 五環式化合物 |
EP18853415.0A EP3680243B1 (en) | 2017-09-07 | 2018-09-05 | Pentacyclic compound |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220019T1 true HRP20220019T1 (hr) | 2022-04-01 |
Family
ID=65517037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220019TT HRP20220019T1 (hr) | 2017-09-07 | 2018-09-05 | Pentaciklički spoj |
Country Status (33)
Country | Link |
---|---|
US (1) | US10239889B1 (hr) |
EP (1) | EP3680243B1 (hr) |
JP (1) | JP6557441B1 (hr) |
KR (1) | KR102307738B1 (hr) |
CN (1) | CN111051316B (hr) |
AR (1) | AR112788A1 (hr) |
AU (1) | AU2018330578B2 (hr) |
BR (1) | BR112020003197A2 (hr) |
CA (1) | CA3072740A1 (hr) |
CL (1) | CL2020000376A1 (hr) |
CO (1) | CO2020001471A2 (hr) |
CY (1) | CY1125355T1 (hr) |
DK (1) | DK3680243T3 (hr) |
ES (1) | ES2903172T3 (hr) |
HR (1) | HRP20220019T1 (hr) |
HU (1) | HUE056791T2 (hr) |
IL (1) | IL272652B (hr) |
JO (1) | JOP20200030A1 (hr) |
LT (1) | LT3680243T (hr) |
MA (1) | MA50093B1 (hr) |
MD (1) | MD3680243T2 (hr) |
MX (1) | MX2020001786A (hr) |
PH (1) | PH12020500341A1 (hr) |
PL (1) | PL3680243T3 (hr) |
PT (1) | PT3680243T (hr) |
RS (1) | RS62796B1 (hr) |
RU (1) | RU2754557C1 (hr) |
SG (1) | SG11202001240XA (hr) |
SI (1) | SI3680243T1 (hr) |
TW (1) | TWI707859B (hr) |
UA (1) | UA125940C2 (hr) |
WO (1) | WO2019049869A1 (hr) |
ZA (1) | ZA202000970B (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药(上海)有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
JP2020533317A (ja) | 2017-09-07 | 2020-11-19 | オーガスタ ユニバーシティ リサーチ インスティテュート,インコーポレーテッド | 特異的akt3活性化剤およびその使用 |
BR112021015975A2 (pt) * | 2019-03-05 | 2021-10-05 | Eisai R&D Management Co., Ltd. | Composto heterocíclico pentacíclico |
CA3129764A1 (en) | 2019-03-05 | 2020-09-10 | Eisai R&D Management Co., Ltd. | Salt of pentacyclic compound and crystals thereof |
EP4069369A4 (en) * | 2019-12-06 | 2024-02-14 | Schrödinger, Inc. | CYCLIC COMPOUNDS AND METHODS OF USE THEREOF |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4187306A (en) * | 1977-07-26 | 1980-02-05 | Bayer Aktiengesellschaft | Benzodiazepine-diones, a process for their production and their use as medicaments |
DD258234A1 (de) * | 1987-03-05 | 1988-07-13 | Univ Leipzig | Verfahren zur herstellung von pyrido/3',2':4,5/thieno/2,3-e/imidazo-/1,2-c/pyrimidinen sowie strukturanaloger -pyrimido/1,2-c/pyrimidine bzw. -1,3-diazepino/1,2-c/pyrimidine |
RU2117670C1 (ru) * | 1988-10-31 | 1998-08-20 | Эйсай Ко., Лтд. | Производные триазоло[1,4]диазепина и способы их получения |
TW197442B (hr) * | 1990-02-08 | 1993-01-01 | Pfizer | |
KR100203456B1 (ko) | 1995-06-20 | 1999-06-15 | 한승수 | 디하이드로에보디아민-에이치씨1를 유효성분으로 함유하는 알츠하이머병에 의한 치매 치료제 |
FR2779652B1 (fr) * | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
CA2584757C (en) * | 2004-10-20 | 2012-07-03 | F. Hoffmann-La Roche Ag | Halogen substituted benzodiazepine derivatives |
JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
US8192080B2 (en) | 2007-01-23 | 2012-06-05 | Tsi Technologies Llc | Microwire-controlled autoclave and method |
-
2018
- 2018-09-05 RU RU2020106798A patent/RU2754557C1/ru active
- 2018-09-05 HU HUE18853415A patent/HUE056791T2/hu unknown
- 2018-09-05 JP JP2019516726A patent/JP6557441B1/ja active Active
- 2018-09-05 IL IL272652A patent/IL272652B/en unknown
- 2018-09-05 US US16/122,116 patent/US10239889B1/en active Active
- 2018-09-05 MA MA50093A patent/MA50093B1/fr unknown
- 2018-09-05 PL PL18853415T patent/PL3680243T3/pl unknown
- 2018-09-05 AU AU2018330578A patent/AU2018330578B2/en active Active
- 2018-09-05 CN CN201880053052.1A patent/CN111051316B/zh active Active
- 2018-09-05 LT LTEPPCT/JP2018/032797T patent/LT3680243T/lt unknown
- 2018-09-05 WO PCT/JP2018/032797 patent/WO2019049869A1/ja unknown
- 2018-09-05 EP EP18853415.0A patent/EP3680243B1/en active Active
- 2018-09-05 SI SI201830467T patent/SI3680243T1/sl unknown
- 2018-09-05 RS RS20220015A patent/RS62796B1/sr unknown
- 2018-09-05 ES ES18853415T patent/ES2903172T3/es active Active
- 2018-09-05 TW TW107131095A patent/TWI707859B/zh active
- 2018-09-05 SG SG11202001240XA patent/SG11202001240XA/en unknown
- 2018-09-05 MD MDE20200725T patent/MD3680243T2/ro unknown
- 2018-09-05 UA UAA202000934A patent/UA125940C2/uk unknown
- 2018-09-05 KR KR1020207004232A patent/KR102307738B1/ko active IP Right Grant
- 2018-09-05 CA CA3072740A patent/CA3072740A1/en active Pending
- 2018-09-05 AR ARP180102517A patent/AR112788A1/es unknown
- 2018-09-05 BR BR112020003197-6A patent/BR112020003197A2/pt unknown
- 2018-09-05 JO JOP/2020/0030A patent/JOP20200030A1/ar unknown
- 2018-09-05 MX MX2020001786A patent/MX2020001786A/es unknown
- 2018-09-05 PT PT188534150T patent/PT3680243T/pt unknown
- 2018-09-05 HR HRP20220019TT patent/HRP20220019T1/hr unknown
- 2018-09-05 DK DK18853415.0T patent/DK3680243T3/da active
-
2020
- 2020-02-11 CO CONC2020/0001471A patent/CO2020001471A2/es unknown
- 2020-02-13 CL CL2020000376A patent/CL2020000376A1/es unknown
- 2020-02-14 ZA ZA2020/00970A patent/ZA202000970B/en unknown
- 2020-02-14 PH PH12020500341A patent/PH12020500341A1/en unknown
-
2022
- 2022-01-10 CY CY20221100025T patent/CY1125355T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20220019T1 (hr) | Pentaciklički spoj | |
HRP20191283T1 (hr) | Diaril makrocikli kao modulatori protein kinaze | |
IL241573B (en) | Transformed histories of [2h]imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidine-4[5h]-one, a pharmaceutical preparation containing them and their use as drugs | |
IL262698B (en) | [1,2-b]Amidazo-converted pyridazines, [1,5-b]imidazo-converted pyridazines, related compounds and their use for the treatment of medical disorders | |
IL261231B (en) | Mcl-1 (r)-4-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2h)-one inhibitors | |
IL288525A (en) | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo-[1,2-a] pyrido [3,4-e] pyrimidine-5(1h)-one, analogs and salts thereof, and methods of use for therapy | |
MX2019013643A (es) | Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona. | |
CL2016002836A1 (es) | Compuestos derivados de pirido pirimidin con actividad moduladora del empalme genico de smn2; composicion farmaceutica y uso en el tratamiento de la atrofia muscular espinal (ame). | |
PH12016501164A1 (en) | Heteroaryl substituted nicotinamide compounds | |
MX2020002711A (es) | Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona. | |
EA201891897A1 (ru) | 1,5-ДИГИДРО-4H-ПИРАЗОЛО[3,4-d]ПИРИМИДИН-4-ОНЫ И 1,5-ДИГИДРО-4H-ПИРАЗОЛО[4,3-c]ПИРИДИН-4-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1 | |
TWI800696B (zh) | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 | |
MX2022001966A (es) | 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9- hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso. | |
IL243269B (en) | Crystals of (sa9,ra6)-a9,9,8,7,a6,5-hexahydro-5-methyl-3-(phenylamino)-2- ((4-(6-fluoropyridin-2-yl)phenyl)methyl ) cyclopent[5,4]imidazo[a-2,1]pyrazolo[e-3,4]pyrimidine-4(h2)-one, their salts and a process for preparing the salts. | |
ZA201902893B (en) | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | |
DOP2018000246A (es) | 5,6,7,8tetrahidro[1,2,4]triazolo[4,3a]piridin3(2h)onas y 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones sustituidas y su uso | |
PL3596080T3 (pl) | Aktywne farmakologicznie podstawione alicyklem pochodne pirazolo[1,5-A]pirymidyny | |
JP2016517877A5 (hr) | ||
AR118235A1 (es) | Heterociclos pentacíclicos | |
IL281956A (en) | History of 6,2-dimethyl-N-(pyridin-4-yl)methyl)imidazo[2,1-B]pyridazin-8-amine and 5,2-dimethyl-N-[(pyridin-4-yl)methyl] Pyrazolo[5,1-A]pyrimidine-7-amine for the treatment of viral infections | |
WO2014193881A8 (en) | Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
IL253427B (en) | The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose | |
WO2017144973A3 (es) | Formulaciones farmacéuticas novedosas que comprenden un inhibidor de pds5 | |
MX2016007494A (es) | Tratamiento de la esclerosis multiple con un derivado de 1,2,4-triazolo [1,5-a] piridina. |